Wyeth Paying $491M To End Criminal, Civil Rapamune Cases

Law360, Chicago (July 30, 2013, 5:44 PM EDT) -- Wyeth Pharmaceuticals Inc. has agreed to shell out $491 million to end a criminal action as well as civil False Claims Act cases alleging it illegally marketed its immunosuppressive drug Rapamune for unapproved uses, the U.S. Department of Justice said Tuesday.

Wyeth, which was acquired by Pfizer Inc. in 2009, also pled guilty to a criminal information alleging it misbranded the prescription drug in violation of the Federal Food, Drug and Cosmetic Act. Under that plea deal, which a federal court in Oklahoma has accepted, Wyeth agreed to pay a $157.58 million criminal fine and forfeit assets of $76 million....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!